Federated Hermes’s Rigel Pharmaceuticals RIGL Stock Holding History

Federated Hermes’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8K	Sell	403 -498	-55%	-$15.4K	﹤0.01%	1803
2026 Q1	$24.4K	Buy	901 +381	+73%	+$12.8K	﹤0.01%	1759
2025 Q4	$22.3K	Sell	520 -21	-4%	-$792	﹤0.01%	1751
2025 Q3	$15.3K	Buy	541 +472	+684%	+$14.1K	﹤0.01%	1836
2025 Q2	$1.29K	Buy	+69	New	+$1.31K	﹤0.01%	1983
2021 Q4	–	Sell	-1,723	Closed	-$63K	–	2291
2021 Q3	$63K	Buy	+1,723	New	+$67.8K	﹤0.01%	1835
2021 Q2	–	Sell	-13	Closed	-$491	–	2152
2021 Q1	$1K	Buy	+13	New	+$515	﹤0.01%	2186
2018 Q3	–	Sell	-1,290	Closed	-$36K	–	2316
2018 Q2	$36K	Buy	+1,290	New	+$45.9K	﹤0.01%	1734
2018 Q1	–	Sell	-51	Closed	-$2K	–	2223
2017 Q4	$2K	Buy	+51	New	+$1.94K	﹤0.01%	2083
2017 Q3	–	Sell	-146	Closed	-$4K	–	2185
2017 Q2	$4K	Sell	146 -34	-19%	-$931	﹤0.01%	1991
2017 Q1	$6K	Buy	+180	New	+$4.59K	﹤0.01%	1907
2015 Q4	–	Sell	-190	Closed	-$5K	–	2146
2015 Q3	$5K	Sell	190 -9	-5%	-$269	﹤0.01%	1790
2015 Q2	$6K	Buy	+199	New	+$7.6K	﹤0.01%	1776
2014 Q3	–	Sell	-117	Closed	-$4K	–	2048
2014 Q2	$4K	Buy	+117	New	+$3.98K	﹤0.01%	1868

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's RIGL Position: Q2 2026 in Review

Federated Hermes reduced its Rigel Pharmaceuticals (RIGL) stake by 55% in Q2 2026, selling an estimated $15.4K and leaving 403 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

Federated Hermes first reported a position in RIGL in Q2 2014 and has held it in 14 quarters since. The position peaked at $63K in Q3 2021. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Federated Hermes held 403 shares of Rigel Pharmaceuticals worth $15.8K as of Q2 2026.
Federated Hermes sold 498 Rigel Pharmaceuticals shares in Q2 2026, an estimated $15.4K.
Rigel Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1803 holding.
Federated Hermes first reported a position in Rigel Pharmaceuticals in Q2 2014 and has held it in 14 quarters since.
Federated Hermes's Rigel Pharmaceuticals position peaked at $63K in Q3 2021.
155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.